IOVA Q4 2019 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$65M

Net Income

-$64M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$57M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$345M

Total Liabilities

$46M

Stockholders' Equity

$299M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$65M	-$35M	-86.3%
Net Income	-$64M	-$33M	-95.1%